GEN Exclusives

More »

GEN News Highlights

Back to Item »

Agennix Stops Phase II/III Talactoferrin Study in Sepsis Due to Higher Death Rates

Move doesn't affect ongoing Phase III studies evaluating recombinant lactoferrin against NSCLC.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?